
About Revapharma LLP
Data last updated:
Revapharma LLP is a limited liability partnership (LLP) based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 February 2020 and has been in existence for over 6 years.
The LLP is registered with the Registrar of Companies (ROC), Delhi, under LLPIN AAR-9430. Its GSTIN is 07ABBFR0512N1ZA (Delhi). The LLP holds 2 GST registrations, all of them active.
The LLP has a total obligation of contribution of ₹1 Lakh. It is led by designated partners Shishant Gupta and Gurpreet Sandhu Singh.
Its latest statement of accounts is for the year ended 31 March 2024. The registered office is at A – 4 Part A Mahipalpur Extended Abadi Of Village Mahipalpur, Main Vasant Kunj Road Opp. To Jagannath Complex, New Delhi, Delhi, India – 110037.
As per the financials filed for FY 2023, the LLP reported a revenue of ₹1.14 Cr, a decline of 84% compared to the previous year. For the same year it recorded EBITDA of ₹11.78 Lakh (EBITDA margin 10.3%).
As per MCA filings, the LLP has open charges of ₹50 Lakh on record. Court records list 1 case involving the LLP, including 1 filed against it.
For more details, the LLP can be reached via its website revapharma.com.
Company details
Contact details
Revapharma LLP's registered office is in New Delhi, Delhi.
- Social Media
- Registered AddressA – 4 Part A Mahipalpur Extended Abadi Of Village Mahipalpur, Main Vasant Kunj Road Opp. To Jagannath Complex, New Delhi, Delhi, India – 110037
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Revapharma LLP
FY 2024 filings availableRevapharma LLP reported revenue of ₹1.14 Cr (down 84% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue fell 84% in the latest year. EBITDA rose 257% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Statement of Account and Solvency | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|
| Income and Expenditure | ||||
| Turnover | ||||
| Other Income | ||||
| Total Income | ||||
| Purchases and Direct Costs | ||||
| Personnel Expenses | ||||
| Administrative Expenses | ||||
| Interest | ||||
| Depreciation | ||||
| Total Expenses | ||||
| Profit Before Tax | ||||
| Tax | ||||
| Profit After Tax | ||||
| Profit Transferred to Partners | ||||
| Assets and Liabilities | ||||
| Partners' Contribution | ||||
| Reserves and Surplus | ||||
| Secured Loans | ||||
| Unsecured Loans | ||||
| Trade Payables | ||||
| Other Liabilities and Provisions | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Loans and Advances | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Statement of Account and Solvency | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|
| Profitability | ||||
| Net Profit Margin | ||||
| Return on Partners' Funds | ||||
| Return on Assets | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Debt to Partners' Funds | ||||
| Interest Coverage | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Turnover Growth | ||||
| Profit Growth | ||||
To see the full financial statements and ratios of Revapharma LLP, buy the company report.
Designated partners of Revapharma LLP
Revapharma has 2 current designated partners and 1 former designated partner. Current designated partners are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shishant Gupta | Designated Partner | 04 Jun 2022 | 4 Years 5 Months | Current |
| Gurpreet Sandhu Singh Also directs: Reva Medicare Private Limited, Akira Pharma Private Limited, Akira Developers Private Limited and 2 more | Designated Partner | 17 Feb 2020 | 6 Years 9 Months | Current |
Peer comparison
Revapharma LLP is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Xenosys Biotech Private Limited | ₹1.15 Cr (FY 2025) | -42.0% | Sanand, Gujarat, India | |||
| Abm Lab Private Limited | ₹1.15 Cr (FY 2020) | 13.0% | New Delhi, Delhi, India | |||
| Bonjour Health Care Private Limited | ₹1.15 Cr (FY 2025) | 11.0% | New Delhi, Delhi, India | |||
| Foray Life Care Private Limited | ₹1.15 Cr (FY 2025) | 51.0% | Bengaluru, Karnataka, India | |||
| Taizi Pharma Private Limited | ₹1.15 Cr (FY 2023) | 184.0% | Bangalore, Karnataka, India | |||
| Revapharma LLPthis company | ₹1.14 Cr (FY 2023) | -84.0% | New Delhi, Delhi, India | |||
| Osr Pharmaceuticals Private Limited | ₹1.14 Cr (FY 2025) | 11.0% | Delhi, India | |||
| Vrihad Health Care Private Limited | ₹1.14 Cr (FY 2024) | 66.0% | Chhattisgarh, India | |||
| Pyramid Formulations Private Limited | ₹1.14 Cr (FY 2023) | 16.0% | Salem, Tamil Nadu, India | |||
| Life Line Biotech Limited | ₹1.14 Cr (FY 2025) | -66.0% | New Delhi, Delhi, India | |||
| Ytiliga Private Limited | ₹1.14 Cr (FY 2024) | 30.0% | Delhi, India |
To see the full peer comparison of Revapharma LLP, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Feb 2021 | 100438533 | Daimler Financial Services India Private Limited | ₹50 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
Revapharma LLP has 1 court case on record: 1 filed against it. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gurugram, Haryana | Civil suit | Filed against the company by M/S Rsa Legal Solutions | Disposed |
To see the full case history of Revapharma LLP, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Revapharma LLP; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Revapharma has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07ABBFR0512N1ZA | Delhi | Active | 13 Jun 2020 |
| 24ABBFR0512N1ZE | Gujarat | Active | 08 Nov 2023 |
To see the full GST registrations and return filing status of Revapharma LLP, buy the company report.
Recent activity
Revapharma LLP has 3 designated partner changes on record since 2020: 2 appointments and 1 cessation. The latest: Nizar Balan ceased to be Designated Partner on 04 Jun 2022.
Frequently asked questions
Revapharma is an active limited liability partnership based in New Delhi, Delhi, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 17 February 2020 (6+ years old) and is registered under LLPIN AAR-9430.
Revapharma has 2 current designated partners:
- Shishant Gupta - Designated Partner
- Gurpreet Sandhu Singh - Designated Partner
The latest financial statements of Revapharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 31 March 2024. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Revapharma is 07ABBFR0512N1ZA, registered in Delhi. The LLP has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 24ABBFR0512N1ZE (Gujarat).
The LLPIN (Limited Liability Partnership Identification Number) of Revapharma is AAR-9430. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Revapharma has 1 court case on record: 1 filed against it.
Revapharma was incorporated on 17 February 2020, making it 6+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Revapharma by revenue are Xenosys Biotech Private Limited, Abm Lab Private Limited, Bonjour Health Care Private Limited, Foray Life Care Private Limited, Taizi Pharma Private Limited and 5 more, all in the Pharma industry (Formulations).
Nizar Balan ceased to be Designated Partner on 04 Jun 2022. Shishant Gupta was appointed as Designated Partner on 04 Jun 2022. Gurpreet Sandhu Singh was appointed as Designated Partner on 17 Feb 2020.
Revapharma can be reached through the website revapharma.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Revapharma is at A – 4 Part A Mahipalpur Extended Abadi Of Village Mahipalpur, Main Vasant Kunj Road Opp. To Jagannath Complex, New Delhi, Delhi, India – 110037.

